High-dose transdermal nicotine replacement for tobacco cessation

American Journal of Health-System Pharmacy

Volumn 71, Issue 8, 2014, Pages 634-638

  Brokowski, Laurie ^a   Chen, Jiahui ^a   Tanner, Sara ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3' HYDROXYCOTININE; COTININE; NICOTINE PATCH; NICOTINE; NICOTINE GUM;

ANGIONEUROTIC EDEMA; APPLICATION SITE EDEMA; APPLICATION SITE ERYTHEMA; APPLICATION SITE IRRITATION; ARTICLE; ASTHENIA; CEREBROVASCULAR ACCIDENT; DIZZINESS; DOSE RESPONSE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSPEPSIA; FOLLOW UP; HEART INFARCTION; HUMAN; MYALGIA; NICOTINE REPLACEMENT THERAPY; SLEEP DISORDER; SMOKING CESSATION; TACHYCARDIA; TOBACCO DEPENDENCE; VISUAL IMPAIRMENT; VOMITING; INTRADERMAL DRUG ADMINISTRATION; PROCEDURES;

ADMINISTRATION, CUTANEOUS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; NICOTINE; SMOKING CESSATION; TOBACCO USE CESSATION PRODUCTS;

EID: 84907199052     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp130543     Document Type: Article

References (21)

1. American Society of Addiction Medicine. Nicotine addiction and tobacco. Public policy statement on nicotine dependence and tobacco. www.asam.org/docs/public-policy-statements/1nicotine-addiction-and-tobacco-rev-10-081.pdf?sfvrsn=0 (accessed 2013 May 1).
2. Centers for Disease Control and Prevention. Smoking-attributable mortality, years of potential life lost, and productivity losses-United States, 2000-2004. MMWR. 2008; 57:1226-8.
3. Fiore MC, Jaén CR, Baker TB et al. Treating tobacco use and dependence: 2008 update. Quick reference guide for clinicians. www.ahrq.gov/professionals/cliniciansproviders/guidelines-recommendations/tobacco/clinicians/reference/tobaqrg.pdf (accessed 2014 Jan 20).
4. Callahan-Lyon P. Nicotine replacement therapy: the CDER experience. www.fda.gov/downloads/Advisory Committees/Committees Meeting Materials/TobaccoProductsScientific AdvisoryCommittee/UCM288284.pdf (accessed 2013 Apr 13).
5. Nicoderm CQ (nicotine transdermal system) package insert. Moon Township, PA: GlaxoSmithKline; 2012.
6. Food and Drug Administration. Clinical pharmacology and biopharmaceutics review: Prostep (nicotine transdermal system) 11 mg/day, 22 mg/day. Application number: NDA 19-983/S012. www.accessdata.fda.gov/drugsatfda- docs/nda/98/19983s012-Prostep-clinphrmr.pdf (accessed 2013 Apr 13).
7. Hurt RD, Dale LC, Offord KP et al. Serum nicotine and cotinine levels during nicotine-patch therapy. Clin Pharmacol Ther. 1993; 54:98-106.
8. Hurt RD, Dale LC, Fredrickson PA et al. Nicotine patch therapy for smoking cessation combined with physician advice and nurse follow-up. One-year outcome and percentage of nicotine replacement. JAMA. 1994; 271:595-600.
9. Benowitz NL, Zevin S, Jacob P III. Suppression of nicotine intake during ad libitum cigarette smoking by high-dose transdermal nicotine. J Pharmacol Exp Ther. 1998; 287:958-62.
10. Hatsukami D, Mooney M, Murphy S et al. Effects of high dose transdermal nicotine replacement in cigarette smokers. Pharmacol Biochem Behav. 2007; 86:132-9.
11. Leischow SJ, Valente SN, Hill AL et al. Effects of nicotine dose and administration method on withdrawal symptoms and side effects during short-term smoking abstinence. Exp Clin Psychopharmacol. 1997; 5:54-64.
12. Ebbert JO, Dale LC, Patten CA et al. Effect of high-dose nicotine patch therapy on tobacco withdrawal symptoms among smokeless tobacco users. Nicotine Tob Res. 2007; 9:43-52.
13. Fredrickson PA, Hurt RD, Lee GM et al. High dose transdermal nicotine therapy for heavy smokers: safety, tolerability and measurement of nicotine and cotinine levels. Psychopharmacology. 1995; 122:215-22.
14. Jorenby DE, Smith SS, Fiore MC et al. Varying nicotine patch dose and type of smoking cessation counseling. JAMA. 1995; 274:1347-52.
15. Dale LC, Hurt RD, Offord KP et al. High-dose nicotine patch therapy. Percentage of replacement and smoking cessation. JAMA. 1995; 274:1353-8.
16. Kalman D, Kahler CW, Tirch D et al. Twelve-week outcomes from an investigation of high-dose nicotine patch therapy for heavy smokers with a past history of alcohol dependence. Psychol Addict Behav. 2004; 18:78-82.
17. Kalman D, Kahler CW, Garvey AJ et al. High-dose nicotine patch therapy for smokers with a history of alcohol dependence: 36-week outcomes. J Subst Abuse Treat. 2006; 30:213-7.
18. Schnoll RA, Wileyto EP, Leone FT et al. High dose transdermal nicotine for fast metabolizers of nicotine: a proof of concept placebo-controlled trial. Nicotine Tob Res. 2013; 15:348-54.
19. Hughes JR, Lesmes GR, Hatsukami DK et al. Are higher doses of nicotine replacement more effective for smoking cessation? Nicotine Tob Res. 1999; 1:169-74.
20. Sachs DP, Benowitz NL, Bostrum AG et al. Percent serum replacement and success of nicotine patch therapy. Am J Resp Crit Care Med. 1995; 151:A688. Abstract.
21. Strasser AA, Pickworth WB, Patterson F et al. Smoking topography predicts abstinence following treatment with nicotine replacement therapy. Cancer Epidemiol Biomarkers Prev. 2004; 13:1800-4.